LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease

De Rijk, 2000, Prevalence of Parkinson's disease in Europe: a collaborative study of population based cohorts. Neurologic Diseases in the Elderly Research Group, Neurology, 54, S21, 10.1212/WNL.54.5.21A Parsian, 2007, Association of α-Synuclein gene haplotypes with Parkinson's disease, Parkinsonism Relat Disord, 13, 343, 10.1016/j.parkreldis.2006.12.006 Zarranz, 2004, The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia, Ann Neurol, 55, 164, 10.1002/ana.10795 Chartier-Harlin, 2004, Alpha-synuclein locus duplication as a cause of familial Parkinson's disease, Lancet, 364, 1167, 10.1016/S0140-6736(04)17103-1 Pals, 2004, Alpha-Synuclein promoter confers susceptibility to Parkinson's disease, Ann Neurol, 56, 591, 10.1002/ana.20268 Leroy, 1998, The ubiquitin pathway in Parkinson's disease, Nature, 395, 451, 10.1038/26652 Ramirez, 2006, Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase, Nat Genet, 38, 1184, 10.1038/ng1884 Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, 44, 601, 10.1016/j.neuron.2004.11.005 Gilks, 2005, A common LRRK2 mutation in idiopathic Parkinson's disease, Lancet, 365, 415 Skipper, 2005, Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease, Hum Mol Genet, 14, 3549, 10.1093/hmg/ddi376 Funayama, 2002, A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1, Ann Neurol, 51, 296, 10.1002/ana.10113 Bosgraaf, 2003, a Ras/GTPase domain in complex proteins, Biochim Biophys Acta, 1643, 5, 10.1016/j.bbamcr.2003.08.008 Smith, 2006, Kinase activity of mutant LRRK2 mediates neuronal toxicity, Nat Neurosci, 9, 1231, 10.1038/nn1776 Fahn, 1987, Elton RL, and Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale, 153 Folstein, 1975, “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 Racette, 1999, Evaluation of a screening questionnaire for genetic studies of Parkinson's disease, Am J Med Genet, 88, 539, 10.1002/(SICI)1096-8628(19991015)88:5<539::AID-AJMG19>3.0.CO;2-S Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, 55, 181, 10.1136/jnnp.55.3.181 Parsian, 1998, Mutation sequence analysis and association studies of α-synuclein in Parkinson’s disease, Neurology, 51, 1757, 10.1212/WNL.51.6.1757 Nichols, 2005, Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease, Lancet, 365, 410 Schaid, 2002, Score tests for association of traits with haplotypes when linkage phase is ambiguous, Am J Hum Genet, 70, 425, 10.1086/338688 Lake, 2003, Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous, Hum Hered, 55, 56, 10.1159/000071811 Zhao, 2006, Genetic dissection of complex traits in silico: approaches, problems, and solutions, Curr Bioinform, 1, 359, 10.2174/157489306777827982 Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457 Zabetian, 2005, A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations, Neurology, 65, 741, 10.1212/01.WNL.0000172630.22804.73 Zabetian, 2006, Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease, Neurology, 67, 697, 10.1212/01.wnl.0000227732.37801.d4 Paisan-Ruiz, 2005, LRRK2 gene in Parkinson disease: mutation analysis and case control association study, Neurology, 65, 696, 10.1212/01.WNL.0000167552.79769.b3 Bialecka, 2005, Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease, Neurosci Lett, 390, 1, 10.1016/j.neulet.2005.07.045 Toft, 2005, LRRK2 mutations and parkinsonism, Lancet, 365, 1229, 10.1016/S0140-6736(05)74809-1 Goldwurm, 2005, The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor, J Med Genet, 42, 10.1136/jmg.2005.035568 Lesage, 2005, French Parkinson's Disease Genetics Study Group. G2019S LRRK2 mutation in French and North African families with Parkinson's disease, Ann Neurol, 58, 784, 10.1002/ana.20636 Clark, 2006, Frequency of LRRK2 mutations in early- and late-onset Parkinson's disease, Neurology, 67, 1786, 10.1212/01.wnl.0000244345.49809.36 Farrer, 2005, LRRK2 mutations in Parkinson's disease, Neurology, 65, 738, 10.1212/01.WNL.0000169023.51764.b0 Ishihara, 2006, Clinical features of Parkinson disease patients with homozygous Leucine-Rich Repeat Kinase 2 G2019S mutations, Arch Neurol, 63, 1250, 10.1001/archneur.63.9.1250 Papapetropoulos, 2006, Clinical heterogeneity of the LRRK2 G2019S mutation, Arch Neurol, 63, 1242, 10.1001/archneur.63.9.1242 Cossu, 2007, LRRK2 mutations and Parkinson's disease in Sardinia – a Mediterranean genetic isolate, Parkinsonism Relat Disord, 13, 17, 10.1016/j.parkreldis.2006.06.010 Paisan-Ruız, 2006, Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium, J Med Genet, 43 Biskup, 2005, Common variants of LRRK2 are not associated with sporadic Parkinson's disease, Ann Neurol, 58, 905, 10.1002/ana.20664 Zhang, 2005, Assessing the power of tag SNPs in the mapping of quantitative trait loci (QTL) with extremal and random samples, BMC Genet, 6, 51, 10.1186/1471-2156-6-51